Literature DB >> 12958580

The role of leukotrienes in nasal allergy.

Ilknur Haberal1, Jacquelynne P Corey.   

Abstract

OBJECTIVE: This review focuses on the role of cysteinyl leukotrienes (cysLTs) in nasal allergy. The purpose was to provide knowledge of the role of cysLTs in the pathophysiology of nasal allergy and the role of antileukotrienes in the treatment of nasal allergies. Materials and methods We conducted a literature review.
RESULTS: The proinflammatory effects of cysLTs have been well described in asthma. Antileukotrienes have proved to be an effective anti-inflammatory treatment for asthma patients. Similar to pathogenesis of asthma, cysLTs exert potent inflammatory effects in the upper airways and play a role in the pathogenesis of allergic rhinitis and other nasal allergies.
CONCLUSION: Antileukotriene treatment appears to be beneficial in nasal allergies. Allergic rhinitis is a complex, IgE-mediated inflammatory disease of the upper airways. It is the most common allergic disease, occurring in 10% to 30% of adults and up to 30% of children. It may be perennial or seasonal. Sneezing, itching, watery rhinorrhea, and nasal obstruction are classic symptoms. It may impair cognition, school/work performance and productivity, behavior, mood, and quality of life. On physical examination, clear secretions, nasal congestion, pink-bluish nasal mucosa, the allergic salute, and allergic shiners may be detected. Allergic rhinitis is a common comorbid condition with asthma, sinusitis, otitis media, nasal polyposis, and respiratory infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12958580     DOI: 10.1016/S0194-5998(03)00601-6

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  9 in total

Review 1.  Optimal management of nasal congestion caused by allergic rhinitis in children: safety and efficacy of medical treatments.

Authors:  Glenis Scadding
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

2.  Diode laser treatment in therapy-resistant allergic rhinitis: impact on nasal obstruction and associated symptoms.

Authors:  Philipp P Caffier; Hans Scherer; Konrad Neumann; Sven Lück; Harald Enzmann; Andreas Haisch
Journal:  Lasers Med Sci       Date:  2010-07-10       Impact factor: 3.161

Review 3.  Role of leukotriene antagonists and antihistamines in the treatment of allergic rhinitis.

Authors:  Bengü Cobanoğlu; Elina Toskala; Ahmet Ural; Cemal Cingi
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.806

Review 4.  Antileukotrienes in upper airway inflammatory diseases.

Authors:  Cemal Cingi; Nuray Bayar Muluk; Kagan Ipci; Ethem Şahin
Journal:  Curr Allergy Asthma Rep       Date:  2015-11       Impact factor: 4.806

5.  Rhinitis in the geriatric population.

Authors:  Jayant M Pinto; Seema Jeswani
Journal:  Allergy Asthma Clin Immunol       Date:  2010-05-13       Impact factor: 3.406

6.  Evaluation of Montelukast for the Treatment of Children With Japanese Cedar Pollinosis Using an Artificial Exposure Chamber (OHIO Chamber).

Authors:  Kazuhiro Hashiguchi; Kimihiro Okubo; Yoichi Inoue; Hirotaka Numaguchi; Kumi Tanaka; Nobuyuki Oshima; Anish Mehta; Chisato Nishida; Itori Saito; George Philip
Journal:  Allergy Rhinol (Providence)       Date:  2018-07-13

7.  Montelukast use over the past 20 years: monitoring of its effects and safety issues.

Authors:  Yong Ju Lee; Chang-Keun Kim
Journal:  Clin Exp Pediatr       Date:  2020-02-05

8.  The study of a possible correlation between serum levels of interleukin 17 and clinical severity in patients with allergic rhinitis.

Authors:  Mai Aly Gharib Aly; Mohamed Tawfik El Tabbakh; Waheed Fawzy Heissam; Said Hamed Abbadi
Journal:  Allergy Rhinol (Providence)       Date:  2017-10-01

9.  Individualized treatment for allergic rhinitis based on key nasal clinical manifestations combined with histamine and leukotriene D4 levels.

Authors:  Congxiang Shen; Fang Chen; Huigang Wang; Xinyu Zhang; Guanxue Li; Zhong Wen
Journal:  Braz J Otorhinolaryngol       Date:  2018-10-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.